Conmed (CNMD) Tops Q1 EPS by 8c; Hikes FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $46.29 +2.01%
EPS Growth %: -7.4%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
OCCI, PMCB, BRID, More
EPS Growth %: -7.4%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
OCCI, PMCB, BRID, More
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q1 EPS of $0.70, $0.08 better than the analyst estimate of $0.62. Revenue for the quarter came in at $242.3 million versus the consensus estimate of $235.77 million.
GUIDANCE:
Conmed sees FY2022 revenue of $1.105-1.15 billion, versus the consensus of $1.09 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler sees Google TPU sales hitting $104BN by 2028
- Zhibao Technology to acquire Malaysian AI computing firm Nexsys Tech
- DeFi Development Corp SOL holdings top 2.5 million after 10% gain
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
